# Edwards Lifesciences Corp: Form 10-Q for the period ended Mar 31, 2019

- Company: [Edwards Lifesciences Corp](/companies/ew.md) (CIK 1099800)
- Form: 10-Q
- Filed: 2019-04-26
- Accepted by EDGAR: Apr 26, 2019, 16:09 ET
- Period: 2019-03-31
- Accession: 0001099800-19-000011
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1099800/000109980019000011/ew10-qq12019.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1099800/000109980019000011/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $993.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-01-01 to 2019-03-31 | $231.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | $761.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $171.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-01-01 to 2019-03-31 | $280.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | $274.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-01-01 to 2019-03-31 | $28.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | $249.7m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | $1.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-01-01 to 2019-03-31 | $1.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-01-01 to 2019-03-31 | 212,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | $1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $42.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2019-01-01 to 2019-03-31 | $5.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-03-31 | $709.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $2.37bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $5.47bn | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $646.5m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2019-03-31 | $593.9m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2019-03-31 | $3.45bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 17,350 characters.

### Overview

We are the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we partner with the world's leading clinicians and researchers and invest in research and development to transform care for those impacted by structural heart disease or who require hemodynamic monitoring during surgery or intensive care. We conduct operations worldwide and are managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Our products are categorized into the following main areas: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural Heart ("Surgical"), and Critical Care.

#### Financial Highlights

Our sales growth was led by our TAVR products, primarily increased sales of the *Edwards SAPIEN 3* transcatheter heart valve in the United States, and our Surgical products, primarily the *INSPIRIS RESILIA* aortic valve in the United States and Japan. Our first quarter 2018 Surgical sales in the United States were reduced by a $34.7 million sales return reserve related to our conversion to a consignment inventory model for surgical valves.

The increase in our net income was primarily driven by the aforementioned sales performance and a reduced tax rate, partially offset by continued research and development investments in our transcatheter structural heart programs.

#### Healthcare Environment, Opportunities, and Challenges

The medical technology industry is highly competitive and continues to evolve. Our success is measured both by the development of innovative products and the value we bring to our stakeholders. We are committed to developing new technologies and providing innovative patient care, and we are committed to defending our intellectual property in support of those developments. In the first three months of 2019, we invested 17.3% of our net sales in research and development.

### New Accounting Standards

For information on new accounting standards, see Note 1 to the "*Consolidated Condensed Financial Statements."*

### Results of Operations

### Net Sales Trends

(dollars in millions)

|  | Three Months Ended March 31, 2019 | Percent Change 2018 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| United States | $562.8 | $479.5 | $83.3 | 17.4% |
| Europe | 234.7 | 230.0 | 4.7 | 2.1% |
| Japan | 98.4 | 92.7 | 5.7 | 6.2% |
| Rest of World | 97.1 | 92.6 | 4.5 | 4.8% |
| International | 430.2 | 415.3 | 14.9 | 3.6% |
| Total net sales | $993.0 | $894.8 | $98.2 | 11.0% |

International net sales include the impact of foreign currency exchange rate fluctuations. The impact of foreign currency exchange rate fluctuations on net sales is not necessarily indicative of the impact on net income due to the corresponding effect of foreign currency exchange rate fluctuations on international manufacturing and operating costs, and our hedging activities. For more information, see Item 3, "*Quantitative and Qualitative Disclosures About Market Risk."*

### Net Sales by Product Group

(dollars in millions)

|  | Three Months Ended March 31, 2019 | Percent Change 2018 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| Transcatheter Aortic Valve Replacement | $597.7 | $551.1 | $46.6 | 8.4% |
| Transcatheter Mitral and Tricuspid Therapies | 4.3 | 0.5 | 3.8 | NM |
| Surgical Structural Heart | 214.7 | 179.5 | 35.2 | 19.6% |
| Critical Care | 176.3 | 163.7 | 12.6 | 7.8% |
| Total net sales | $993.0 | $894.8 | $98.2 | 11.0% |

NM - Not meaningful

### Transcatheter Aortic Valve Replacement

Net sales of TAVR products increased for the three months ended March 31, 2019 due primarily to:

- higher sales of the *Edwards SAPIEN 3* valve, particularly in the United States, driven by strong therapy adoption; and
- higher sales of the *Edwards SAPIEN 3 Ultra System* following its regulatory approval in Europe (November 2018) and the United States (December 2018);

partially offset by

- foreign currency exchange rate fluctuations, which decreased net sales for the three months ended March 31, 2019 by $14.7 million, due primarily to the weakening of the Euro against the United States dollar.

Clinicians are continuing to treat patients through the PARTNER 3 Trial for low-risk patients with severe aortic stenosis in the United States, which we began enrolling late in the third quarter of 2018. We are also continuing to enroll the United States pivotal trial to study *CENTERA* for severe, symptomatic aortic stenosis patients at intermediate risk of open-heart surgery.

### Transcatheter Mitral and Tricuspid Therapies

Net sales of TMTT products increased for the three months ended March 31, 2019 due primarily to the launch of the *Edwards PASCAL* transcatheter valve repair system in Europe.

### Surgical Structural Heart

Net sales of Surgical increased for the three months ended March 31, 2019 due primarily to:

- increased sales of aortic tissue valves in the United States and Japan, primarily the *INSPIRIS RESILIA* aortic valve;

partially offset by:

- sales return reserves in the United States in 2018 related to our conversion to a consignment inventory model; and
- foreign currency exchange rate fluctuations, which decreased net sales for the three months ended March 31, 2019 by $6.8 million, due primarily to the weakening of the Euro against the United States dollar.

### Critical Care

The increase in net sales of Critical Care products was driven by our *HemoSphere* advanced monitoring platform, primarily in the United States, partially offset by foreign currency exchange rate fluctuations, which decreased net sales for the three months ended March 31, 2019 by $4.6 million, due primarily to the weakening of the Euro against the United States dollar.

On April 18, 2019, we completed the acquisition of CAS Medical Systems, Inc. ("CASMED"). CASMED is a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain.

### Gross Profit

The increase in gross profit as a percentage of net sales for the three months ended March 31, 2019 was driven primarily by:

- a 1.8 percentage point increase due to the impact of foreign currency exchange rate fluctuations, including the settlement of foreign currency hedging contracts;
- a 0.4 percentage point increase due to an improved product mix, primarily in the United States, driven by TAVR products; and
- the prior year impact of converting to a consignment inventory model for surgical valves;

partially offset by:

- continued investments in our manufacturing capacity.

### Selling, General, and Administrative ("SG&A") Expenses

The increase in SG&A expenses for the three months ended March 31, 2019 was due primarily to higher field personnel-related costs, partially offset by the impact of foreign currency, which decreased expenses by $6.6 million, primarily due to the weakening of the Euro against the United States dollar.

### Research and Development ("R&D") Expenses

The increase in R&D expenses and ratio as a percentage of net sales for the three months ended March 31, 2019 was due primarily to continued investments in our transcatheter structural heart programs, including spending on clinical trials.

### Change in Fair Value of Contingent Consideration Liabilities, net

The change in fair value of contingent consideration liabilities resulted in expense of $6.7 million and $3.8 million for three months ended March 31, 2019 and 2018, respectively. The increase was primarily due to changes in the assumptions used to estimate the fair value of the liabilities, primarily adjustments to discount rates, and accretion of interest due to the passage of time. For further information, see Note 8 to the "*Consolidated Condensed Financial Statements."*

### Special Charge (Gain)

For information on special charge (gain), see Note 5 to the "*Consolidated Condensed Financial Statements."*

### Other Income, net

(in millions)

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Foreign exchange gains, net | $(2.0) | $(4.2) |
| Loss on investments | 0.1 | 0.9 |
| Other | 0.1 | 0.2 |
| Other income, net | $(1.8) | $(3.1) |

The net foreign exchange gains relate primarily to the foreign currency fluctuations in our global trade and intercompany receivable and payable balances, offset by the gains and losses on derivative instruments intended as an economic hedge of those exposures.

The loss on investments primarily represents our net share of gains and losses in investments accounted for under the equity method, and realized gains and losses on our money market accounts and equity securities.

### Provision for Income Taxes

The provision for income taxes consists of provisions for federal, state, and foreign income taxes. We operate in an international environment with significant operations in various locations outside the United States, which have statutory tax rates lower than the United States tax rate. Accordingly, the consolidated income tax rate is a composite rate reflecting the earnings in the various locations and the applicable rates.

Our effective income tax rate was 10.2% and 21.6% for the three months ended March 31, 2019 and 2018, respectively. The effective rate for the three months ended March 31, 2019 is lower than the federal statutory rate of 21% primarily due to the tax benefit from employee share-based compensation and foreign earnings taxed at lower rates. The effective rate for the three months ended March 31, 2018 included expense of $24.0 million related to the adjustment of the estimated provisional amounts recorded at December 31, 2017 in accordance with SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act. The effective rates for the three months ended March 31, 2019 and 2018 include a $19.0 million and $14.2 million tax benefit from employee share-based compensation, respectively.

The IRS began its examination of the 2015 and 2016 tax years during the fourth quarter of 2018 and its examination of the 2017 tax year during the first quarter of 2019.

We strive to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While we have accrued for matters we believe are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, we may later decide to challenge any assessments, if made, and may exercise our right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. We believe that adequate amounts of tax and related penalty and interest have been provided in income tax expense for any adjustments that may result from our uncertain tax positions. For further information, see Note 14 to the "*Consolidated Condensed Financial Statements."*

During 2018, we executed an Advance Pricing Agreement between the United States and Switzerland governments for tax years 2009 through 2020 covering various transfer pricing matters and we have updated our transfer pricing policies accordingly. Certain intercompany transactions covering tax years 2015 through 2018 were not resolved and those related tax positions remain uncertain. These transfer pricing matters may be significant to our consolidated condensed financial statements.

### Liquidity and Capital Resources

Our sources of cash liquidity include cash and cash equivalents, short-term investments, amounts available under credit facilities, and cash from operations. We believe that these sources are sufficient to fund the current requirements of working capital, capital expenditures, and other financial commitments for the next twelve months. However, we periodically consider various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other market conditions.

As of March 31, 2019, cash and cash equivalents and short-term investments held in the United States and outside the United States were $399.8 million and $563.2 million, respectively. Our intent is to repatriate approximately $550.0 million of our foreign earnings by August 2019.

On April 18, 2019, we acquired CAS Medical Systems, Inc. for an aggregate cash purchase price of $2.45 per share of common stock, or an equity value of approximately $100 million. For more information, see Note 7 to the "*Consolidated Condensed Financial Statements."*

Certain of our business acquisitions involve contingent consideration arrangements. Payment of additional consideration in the future may be required, contingent upon the acquired company reaching certain performance milestones, such as attaining specified revenue levels, achieving product development targets, or obtaining regulatory approvals. For further information, see Note 8 to the "*Consolidated Condensed Financial Statements."*

In April 2018, we entered into a Five-Year Credit Agreement ("the Credit Agreement") which matures on April 28, 2023. The Credit Agreement provides up to an aggregate of $750.0 million in borrowings in multiple currencies. Subject to certain terms and conditions, we may increase the amount available under the Credit Agreement by up to an additional $250.0 million in the aggregate. As of March 31, 2019, there were no borrowings outstanding under the Credit Agreement.

In June 2018, we issued $600.0 million of 4.300% fixed-rate unsecured senior notes (the "2018 Notes") due June 15, 2028. As of March 31, 2019, the total carrying value of the 2018 Notes was $593.9 million.

From time to time, we repurchase shares of our common stock under share repurchase programs authorized by the Board of Directors. We consider several factors in determining when to execute share repurchases, including, among other things, expected dilution from stock plans, cash capacity, and the market price of our common stock. During 2019, we repurchased a total of 34 thousand shares at an aggregate cost of $5.0 million, and as of March 31, 2019, we had remaining authority to purchase $489.6 million of our common stock.

At March 31, 2019, there had been no material changes in our significant contractual obligations and commercial commitments as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Consolidated Cash Flows - For the three months ended March 31, 2019 and 2018:

Net cash flows provided by **operating activities** of $1.5 million for the three months ended March 31, 2019 decreased $149.8 million over the same period last year due primarily to payment of $180.0 million for a litigation settlement and higher working capital needs in 2019, partially offset by improved operating performance in 2019.

Net cash used in **investing activities** of $49.5 million for the three months ended March 31, 2019 consisted primarily of (1) capital expenditures of $42.2 million, (2) a $35.0 million payment for an option to acquire a company, and (3) a $16.8 million payment to acquire certain early-stage transcatheter intellectual property and associated clinical and regulatory experience, partially offset by net proceeds from investments of $42.9 million.

Net cash provided by investing activities of $220.3 million for the three months ended March 31, 2018 consisted primarily of net proceeds from investments of $275.9 million, partially offset by capital expenditures of $43.2 million and a $10.0 million contingent consideration milestone payment associated with the acquisition of Harpoon Medical, Inc.

Net cash provided by **financing activities** of $44.4 million for the three months ended March 31, 2019 consisted primarily of proceeds from stock plans of $45.0 million.

Net cash provided by financing activities of $40.9 million for the three months ended March 31, 2018 consisted primarily of proceeds from stock plans of $44.8 million, partially offset by purchases of treasury stock of $2.1 million,

### Critical Accounting Policies and Estimates

The consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated condensed financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 39-41 in Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations,*" of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no significant changes from the information discussed therein.

## Market risk

As filed, 1,104 characters.

### Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk

For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A "*Quantitative and Qualitative Disclosures About Market Risk*" on pages 42-44 of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no significant changes from the information discussed therein.

### Investment Risk

We are exposed to investment risks related to changes in the underlying financial condition and credit capacity of certain of our investments. As of March 31, 2019, we had $683.9 million of investments in fixed-rate debt securities of various companies, of which $430.1 million were long-term. In addition, we had $23.6 million of investments in equity instruments of public and private companies. Should these companies experience a decline in financial condition or credit capacity, or fail to meet certain development milestones, a decline in the investments' value may occur, resulting in unrealized or realized losses.

## Controls and procedures

As filed, 1,690 characters.

**Evaluation of Disclosure Controls and Procedures.** Our management, including the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2019. Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded as of March 31, 2019 that our disclosure controls and procedures are effective in providing reasonable assurance that the information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in our internal controls over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We implemented internal controls to ensure we adequately evaluated our contracts and properly assessed the impact of the new accounting standard related to leases on our financial statements to facilitate its adoption on January 1, 2019. There were no significant changes to our internal control over financial reporting due to the adoption of the new standard.

## Risk factors

As filed, 166 characters.

There have been no material changes to the risk factors under Part I, Item 1A "*Risk Factors*" in our Annual Report on Form 10-K for the year ended December 31, 2018.

Filed Apr 26, 2019.
Source: SEC EDGAR, the filing index for accession 0001099800-19-000011. Last ingested by Listed: Nov 15, 2026, 03:19 ET. No prices; not investment advice.
